MDPI and ACS Style
Irelli, A.; Parisi, A.; D’Orazio, C.; Sidoni, T.; Rotondaro, S.; Patruno, L.; Pavese, F.; Bafile, A.; Resta, V.; Pizzorno, L.;
et al. Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. Cancers 2022, 14, 3003.
https://doi.org/10.3390/cancers14123003
AMA Style
Irelli A, Parisi A, D’Orazio C, Sidoni T, Rotondaro S, Patruno L, Pavese F, Bafile A, Resta V, Pizzorno L,
et al. Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. Cancers. 2022; 14(12):3003.
https://doi.org/10.3390/cancers14123003
Chicago/Turabian Style
Irelli, Azzurra, Alessandro Parisi, Carla D’Orazio, Tina Sidoni, Silvia Rotondaro, Leonardo Patruno, Francesco Pavese, Alberto Bafile, Valter Resta, Laura Pizzorno,
and et al. 2022. "Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status" Cancers 14, no. 12: 3003.
https://doi.org/10.3390/cancers14123003